| IUPAC name
| Other names
|3D model (Jmol)||Interactive image|
|Molar mass||421.50 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.
- Mulvihill, MJ; Cooke, A; Rosenfeld-Franklin, M; Buck, E; Foreman, K; Landfair, D; O'Connor, M; Pirritt, C; et al. (2009). "Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor". Future medicinal chemistry. 1 (6): 1153–71. doi:10.4155/fmc.09.89. PMID 21425998.
- "Linsitinib". NCI Drug Dictionary. National Cancer Institute. Retrieved October 16, 2012.
- "OSI Pharmaceuticals, LLC". Astellas Pharma. Retrieved October 16, 2012.
- "Linsitinib". National Institutes of Health's clinicaltrials.gov. Retrieved October 16, 2012.